NORCROSS, Ga.--(BUSINESS WIRE)--Point-of-care testing with the LuViva® Advance Cervical Scan developed by Guided Therapeutics, Inc., (OTCBB: GTHP) (OTCQB: GTHP) combined with human papillomavirus (HPV) testing, could optimize early detection of cervical cancer and reduce by approximately one-third the number of unnecessary biopsies that result from the false positive rate of Pap tests, according to an analysis presented at the American Congress of Obstetricians and Gynecologists 60th Annual Clinical Meeting in San Diego.
